2. Introduction CKD-MBD

3. Regulation of PTH Secretion

5. Factors Contributing to Pathogenesis of Secondary Hyperparathyroidism

6. Clinical Manifestations Associated With Elevated PTH in CKD-MBD

7. Vitamin D Metabolism

8. Determinants of Vitamin D Status

9. Clinical Practice Guidelines for CKD-MBD

11. Lack of Consensus on Normal Ranges of Vitamin D

12. Vitamin D Toxicity

13. Treatment Goals for Secondary Hyperparathyroidism in Patients With CKD

14. Managing Serum Levels of Phosphate

15. Treatment Options VDRAs and Calcimimetics

16. K/DOQI Recommendations for Vitamin D Supplementation in CKD (Stages 3 and 4)

17. VDRAs vs Placebo in Nondialysis Patients With CKD Stages 3 to 5

18. Paricalcitol vs Calcitriol for Secondary Hyperparathyroidism in Stage 3 or 4 CKD

19. Novel Therapy Extended-Release Calcifediol

20. Oral Extended-Release Calcifediol in Treatment of SHPT in Stage 3 or 4 CKD